142 related articles for article (PubMed ID: 36149536)
1. Combine use of glucocorticoid with other immunosuppressants is a risk factor for Pneumocystis jirovecii pneumonia in autoimmune inflammatory disease patients: a meta-analysis.
Wang H; Shui L; Chen Y
Clin Rheumatol; 2023 Jan; 42(1):269-276. PubMed ID: 36149536
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid.
Chew LC; Maceda-Galang LM; Tan YK; Chakraborty B; Thumboo J
J Clin Rheumatol; 2015 Mar; 21(2):72-5. PubMed ID: 25710857
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases.
Braga BP; Prieto-González S; Hernández-Rodríguez J
Med Clin (Barc); 2019 Jun; 152(12):502-507. PubMed ID: 30853123
[TBL] [Abstract][Full Text] [Related]
4. Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.
Ye WL; Tang N; Wen YB; Li H; Li MX; Du B; Li XM
Int Urol Nephrol; 2016 Nov; 48(11):1863-1871. PubMed ID: 27351666
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics of Pneumocystis carinii pneumonia in children with systemic lupus erythematosus].
Tang XY; Li J; Dong F; Song HM
Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):920-4. PubMed ID: 24495763
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy.
Fritzsche C; Riebold D; Munk-Hartig A; Klammt S; Neeck G; Reisinger E
Scand J Rheumatol; 2012 May; 41(3):208-13. PubMed ID: 22400983
[TBL] [Abstract][Full Text] [Related]
7. Aetiology and prognostic risk factors of mortality in patients with pneumonia receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study.
Li L; Hsu SH; Gu X; Jiang S; Shang L; Sun G; Sun L; Zhang L; Wang C; Ren Y; Wang J; Pan J; Liu J; Bin C
BMJ Open; 2020 Oct; 10(10):e037419. PubMed ID: 33109645
[TBL] [Abstract][Full Text] [Related]
8. Changing epidemiology of Pneumocystis pneumonia, Northern Ireland, UK and implications for prevention, 1 July 2011-31 July 2012.
Patterson L; Coyle P; Curran T; Verlander NQ; Johnston J
J Med Microbiol; 2017 Nov; 66(11):1650-1655. PubMed ID: 29039305
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis pneumonia in patients treated with rituximab.
Martin-Garrido I; Carmona EM; Specks U; Limper AH
Chest; 2013 Jul; 144(1):258-265. PubMed ID: 23258406
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: Usefulness of lymphocyte subtyping.
Li Y; Ghannoum M; Deng C; Gao Y; Zhu H; Yu X; Lavergne V
Int J Infect Dis; 2017 Apr; 57():108-115. PubMed ID: 28223177
[TBL] [Abstract][Full Text] [Related]
11. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis carinii pneumonia in patients with connective tissue disease.
Li J; Huang XM; Fang WG; Zeng XJ
J Clin Rheumatol; 2006 Jun; 12(3):114-7. PubMed ID: 16755237
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Pneumocystis jirovecii Pneumonia in Patients With Rheumatoid Arthritis and a Prophylactic Indication of Trimethoprim/Sulfamethoxazole.
Yukawa K; Nagamoto Y; Watanabe H; Funaki M; Iwahashi M; Yamana J; Sasaki R; Yamana S
J Clin Rheumatol; 2018 Oct; 24(7):355-360. PubMed ID: 29664819
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention.
Sowden E; Carmichael AJ
BMC Infect Dis; 2004 Oct; 4():42. PubMed ID: 15488151
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
17. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.
Green H; Paul M; Vidal L; Leibovici L
Mayo Clin Proc; 2007 Sep; 82(9):1052-9. PubMed ID: 17803871
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jirovecii Pneumonia in Patients With Metastatic Prostate Cancer on Corticosteroids for Malignant Spinal Cord Compression: Two Case Reports and a Guideline Review.
Duarte C; Gilbert D; Sheridan AD; PharmaD SDW; Lam ET
Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212136
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
Ghembaza A; Vautier M; Cacoub P; Pourcher V; Saadoun D
Chest; 2020 Dec; 158(6):2323-2332. PubMed ID: 32502592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
